Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
71
NBY Quote, Financials, Valuation and Earnings
Last price:
$4.68
Seasonality move
:
-0.28%
Day range:
$4.37 - $5.24
52-week range:
$0.46 - $6.47
Dividend yield:
0%
P/E ratio:
7.68x
P/S ratio:
8.88x
P/B ratio:
1.50x
Volume:
1.1M
Avg. volume:
1.6M
1-year change:
784.46%
Market cap:
$575.9M
Revenue:
$9.8M
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
|
YCBD
cbdMD, Inc.
|
$4.7M | -- | 3.2% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $682.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
SAVA
Cassava Sciences, Inc.
|
$2.20 | $8.00 | $106.3M | -- | $0.00 | 0% | 2.69x |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
|
YCBD
cbdMD, Inc.
|
$1.66 | $2.00 | $14.8M | -- | $0.00 | 0% | 0.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.880 | -- | 2.21x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
|
YCBD
cbdMD, Inc.
|
9.72% | 3.470 | 7.22% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
YCBD
cbdMD, Inc.
|
$2.5M | -$685.8K | -43.37% | -57.5% | -14.53% | -$243.5K |
NovaBay Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns NBY or OGEN?
Oragenics, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NBY or OGEN?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -81.4%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 141.11%. Given that Oragenics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is NBY or OGEN More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock NBY or OGEN?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or OGEN?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Oragenics, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 8.88x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NBY or PTN?
Palatin Technologies has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About NBY or PTN?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -81.4%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is NBY or PTN More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NBY or PTN?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or PTN?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Palatin Technologies quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Palatin Technologies's net income of --. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 8.88x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NBY or SAVA?
Cassava Sciences, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About NBY or SAVA?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -81.4%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 263.64%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 SAVACassava Sciences, Inc.1 0 0 -
Is NBY or SAVA More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.081, suggesting its less volatile than the S&P 500 by 208.123%.
-
Which is a Better Dividend Stock NBY or SAVA?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or SAVA?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Cassava Sciences, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 8.88x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
-
Which has Higher Returns NBY or TOVX?
Theriva Biologics, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of --. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NBY or TOVX?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -81.4%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NBY or TOVX More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock NBY or TOVX?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or TOVX?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 8.88x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
-
Which has Higher Returns NBY or YCBD?
cbdMD, Inc. has a net margin of -255.85% compared to NovaBay Pharmaceuticals, Inc.'s net margin of -14.4%. NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03% beat cbdMD, Inc.'s return on equity of -57.5%.
Company Gross Margin Earnings Per Share Invested Capital NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M YCBDcbdMD, Inc.53.28% -$0.08 $8M -
What do Analysts Say About NBY or YCBD?
NovaBay Pharmaceuticals, Inc. has a consensus price target of $0.85, signalling downside risk potential of -81.4%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 20.48%. Given that cbdMD, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBYNovaBay Pharmaceuticals, Inc.1 0 0 YCBDcbdMD, Inc.0 0 0 -
Is NBY or YCBD More Risky?
NovaBay Pharmaceuticals, Inc. has a beta of 0.569, which suggesting that the stock is 43.103% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.218, suggesting its more volatile than the S&P 500 by 121.825%.
-
Which is a Better Dividend Stock NBY or YCBD?
NovaBay Pharmaceuticals, Inc. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBY or YCBD?
NovaBay Pharmaceuticals, Inc. quarterly revenues are $521K, which are smaller than cbdMD, Inc. quarterly revenues of $4.7M. NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M is lower than cbdMD, Inc.'s net income of -$680K. Notably, NovaBay Pharmaceuticals, Inc.'s price-to-earnings ratio is 7.68x while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals, Inc. is 8.88x versus 0.43x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M YCBDcbdMD, Inc.0.43x -- $4.7M -$680K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
